Asia Pacific Pharmacovigilance Market was worth USD 0.930 Billion in 2018 and estimated to be growing at a CAGR of 14.86%, to reach USD 1.86 billion by 2023. Pharmacovigilance services include the drug development activities ranging from its discovery to commercialization. Pharmaceutical companies are collaborating with BPOs and CROs to identify ways for cost reduction and optimising the operational expenses. Outsourcing helps accomplish better monitoring through regulatory compliance, higher quality, better productivity, and improved strategic outcomes.
Major pharmaceutical companies are involved in extensive R&D initiatives for development of innovative therapeutic molecules. This has resulted in increased rate of drug development. Manufacturers are now focusing on remodeling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for pharmacovigilance services during the forecast period.
The market for Pharmacovigilance is broadly categorized into clinical trial phase and service provider. By clinical trial phase the market is divided into pre-clinical, phase I, phase II, phase III, phase IV. Phase III and Phase IV are expected to grow at a high CAGR. By service provider the market is classified into in-house and contract outsourcing.Contract outsourcing holds a major share of the market revenue. On the basis of geography, the market is analysed under various regions namely China, India, Japan, South Korea and Australia. Asia Pacific is expected to grow at the highest CAGR. Growing demand for strict health care regulations, presence of huge patient base and increasing number of clinical trials conducted will boost regional pharmacovigilance market share.
Major industry players include Boehringer Ingelheim, Accenture, Bristol-Myers Squibb, Covance, ICON, PAREXEL, Quintiles, United BioSource, Synowlwedge and Cognizant Technology Solutions Corporation.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Clinical trial phase
5.1.1 Introduction
5.1.2 Pre-clinical
5.1.3 Phase I
5.1.4 Phase II
5.1.5 Phase III
5.1.6 Phase IV
5.1.7 Y-o-Y Growth Analysis, By Clinical trial phase
5.1.8 Market Attractiveness Analysis, By Clinical trial phase
5.1.9 Market Share Analysis, By Clinical trial phase
5.2 Service provider
5.2.1 Introduction
5.2.2 In-house
5.2.3 Contract outsourcing
5.2.4 Y-o-Y Growth Analysis, By Service provider
5.2.5 Market Attractiveness Analysis, By Service provider
5.2.6 Market Share Analysis, By Service provider
5.3 Method
5.3.1 Spontaneous Reporting
5.3.2 Intensified ADR Reporting
5.3.3 Targeted Spontaneous Reporting
5.3.4 Cohort Event Monitoring
5.3.5 EHR Mining
5.3.5 Y-o-Y Growth Analysis, By Method
5.3.6 Market Attractiveness Analysis, By Method
5.3.7 Market Share Analysis, By Method
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Clinical trial phase
6.1.3.3 By Service provider
6.1.3.4 By Method
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Clinical trial phase
6.1.4.3 By Service provider
6.1.4.4 By Method
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Clinical trial phase
6.1.5.3 By Service provider
6.1.5.4 By Method
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Boehringer Ingelheim
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Accenture
8.3 Bristol-Myers Squibb
8.4 Covance
8.5 ICON
8.6 PAREXEL
8.7 Quintiles
8.8 United BioSource
8.9 Synowlwedge
8.10 Cognizant Technology Solutions Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
